Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be
randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences